Results 81 to 90 of about 289,586 (356)

Structural Insights From HIV-Antibody Co-Evolution And Related Immunization Studies [PDF]

, 2018
Human immunodeficiency virus type 1 (HIV-1) is a rapidly evolving pathogen and causes the acquired immunodeficiency syndrome (AIDS) in humans. There are ~30-35 million people infected with HIV around the world, and ~25 million have died since the first ...
Fera, Daniela, Morriss, Julia W., , \u2719, Nguyen, Diep, , \u2719, Ton, Therese, , \u2719, Zhou, Jeffrey O., , \u2719   +4 more
core   +1 more source

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection [PDF]

Current Opinion in HIV and AIDS, 2014
Detailed genetic and structural characterization has revealed that broadly neutralizing antibodies (bnAbs) against HIV-1 have unusually high levels of somatic hypermutation, long CDRH3 domains, and the ability to target one of four sites of vulnerability on the HIV-1 envelope (Env) glycoproteins.
Cynthia A. Derdeyn, Penny L. Moore, Lynn Morris   +2 more
openaire   +3 more sources

Current trends in single‐cell RNA sequencing applications in diabetes mellitus

FEBS Open Bio, EarlyView.
Single‐cell RNA sequencing is a powerful approach to decipher the cellular and molecular landscape at a single‐cell resolution. The rapid development of this technology has led to a wide range of applications, including the detection of cellular and molecular mechanisms and the identification and introduction of novel potential diagnostic and ...
Seyed Sajjad Zadian, Khodakaram Jahanbin, Shekoofeh Nikooei, Marzieh Rostaminejad, Arezoo Rahimi, Pedram Abdizadeh, Behnam Alipoor   +6 more
wiley   +1 more source

In vivo Neutralization of Pro-inflammatory Cytokines During Secondary Streptococcus pneumoniae Infection Post Influenza A Virus Infection [PDF]

, 2019
An overt pro-inflammatory immune response is a key factor contributing to lethal pneumococcal infection in an influenza pre-infected host and represents a potential target for therapeutic intervention.
Boehme, Julia D., Bruder, Dunja, Christen, Henrike, Guzmán, Carlos A., Hernandez-Vargas, Esteban A., Kershaw, Olivia, Schreiber, Jens, Sharma-Chawla, Niharika, Stegemann-Koniszewski, Sabine   +8 more
core   +1 more source

CD9‐association with PIP2 areas is regulated by a CD9 salt bridge

FEBS Open Bio, EarlyView.
The tetraspanin CD9 has an intracellular salt bridge. If CD9 opens, open‐CD9 moves from PIP2‐rich areas to regions populated by its interaction partner EWI‐2. Hence, the state of the salt bridge regulates the distribution of CD9 and by this CD9‐EWI‐2 complex formation.
Yahya Homsi, Sara C. Konopka, Thorsten Lang   +2 more
wiley   +1 more source

Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design

Cell Reports, 2018
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typically take years to develop. Longitudinal analyses of both neutralizing antibody lineages and viruses at serial time points during infection provide a ...
Kimmo Rantalainen, Zachary T. Berndsen, Sasha Murrell, Liwei Cao, Oluwarotimi Omorodion, Jonathan L. Torres, Mengyu Wu, Jeffrey Umotoy, Jeffrey Copps, Pascal Poignard, Elise Landais, James C. Paulson, Ian A. Wilson, Andrew B. Ward   +13 more
doaj  

Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive neurological disorder with limited treatment options. We report a 54‐year‐old female with decade‐long, progressive HAM/TSP, previously refractory to rituximab, who experienced worsening spastic paraparesis and neurogenic bladder dysfunction.
Jiahui Zeng, Wotu Tian, Jingran Yang, Yanping Yang, Li Cao, Xinghua Luan   +5 more
wiley   +1 more source

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

npj Vaccines
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens.
Allan C. deCamp, Martin M. Corcoran, William J. Fulp, Jordan R. Willis, Christopher A. Cottrell, Daniel L. V. Bader, Oleksandr Kalyuzhniy, David J. Leggat, Kristen W. Cohen, Ollivier Hyrien, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Farhad Rahaman, Angela Lombardo, Vincent Philiponis, Rachael E. Whaley, Aaron Seese, Joshua Brand, Alexis M. Ruppel, Wesley Hoyland, Celia R. Mahoney, Alberto Cagigi, Alison Taylor, David M. Brown, David R. Ambrozak, Troy Sincomb, Tina-Marie Mullen, Janine Maenza, Orpheus Kolokythas, Nadia Khati, Jeffrey Bethony, Mario Roederer, David Diemert, Richard A. Koup, Dagna S. Laufer, Juliana M. McElrath, Adrian B. McDermott, Gunilla B. Karlsson Hedestam, William R. Schief   +41 more
doaj   +1 more source

Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

, 2016
This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core   +1 more source

Neutralizing Antibody Response and SARS Severity

Emerging Infectious Diseases, 2005
Using the Taiwan nationwide laboratory-confirmed severe acute respiratory syndrome (SARS) database, we analyzed neutralizing antibody in relation to clinical outcomes. With a linear mixed model, neutralizing antibody titer was shown to peak between week 5 and week 8 after onset and to decline thereafter, with a half-life of 6.4 weeks.
Ho, Mei-Shang, Chen, Wei-Ju, Chen, Hour-Young, Lin, Szu-Fong, Wang, Min-Chin, Di, Jiali, Lu, Yen-Ta, Liu, Ching-Lung, Chang, Shan-Chwen, Chao, Chung-Liang, King, Chwan-Chuen, Chiou, Jeng-Min, Su, Ih-Jen, Yang, Jyh-Yuan   +13 more
openaire   +5 more sources